众生药业(002317) - 2024 Q3 - 季度财报

Financial Performance - Revenue for Q3 2024 was CNY 543,655,317.04, a decrease of 7.70% compared to the same period last year[3] - Net profit attributable to shareholders was CNY 61,392,645.92, down 13.46% year-on-year[3] - Net profit excluding non-recurring gains and losses was CNY 14,719,589.15, a significant decline of 79.17% compared to the previous year[3] - Total operating revenue for the third quarter of 2024 was CNY 1,908,022,039.84, a decrease of 7.87% from CNY 2,071,278,555.78 in the same period last year[20] - Operating profit decreased to CNY 236,330,273.87, down 25.14% from CNY 315,884,900.52 year-over-year[21] - Net profit for the third quarter was CNY 135,910,863.59, a decline of 51.24% compared to CNY 279,214,968.42 in the previous year[21] - The net profit attributable to the parent company for Q3 2024 is ¥148,802,427.39, a decrease of 46.7% compared to ¥279,495,705.55 in the same period last year[22] - The total comprehensive income for Q3 2024 is ¥135,462,397.95, down from ¥282,956,241.04 in Q3 2023, reflecting a decline of 52.2%[22] - The basic earnings per share for Q3 2024 is ¥0.18, compared to ¥0.34 in Q3 2023, indicating a decrease of 47.1%[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,820,046,447.21, reflecting a decrease of 9.89% from the end of the previous year[3] - The company’s total liabilities decreased significantly, with short-term borrowings down 100% to CNY 0 as a result of repayment[7] - Total liabilities decreased to CNY 1,276,882,550.22 from CNY 1,932,845,785.58, reflecting a reduction of 33.93%[19] - The company's total equity increased slightly to CNY 4,543,163,896.99 from CNY 4,525,676,613.51, representing a growth of 0.39%[19] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 300,460,401.93, an increase of 439.98%[3] - Net cash flow from operating activities increased by 439.98% to 300,460,401.93, attributed to cost reductions in response to centralized procurement and last year's early raw material purchases[8] - The net cash flow from operating activities for Q3 2024 is ¥300,460,401.93, significantly up from ¥55,643,062.22 in the same period last year, representing an increase of 438.5%[23] - The net cash flow from investment activities for Q3 2024 is ¥120,624,174.08, a turnaround from a negative cash flow of ¥189,399,577.93 in the same period last year[23] - The net cash flow from financing activities for Q3 2024 is -¥862,477,661.14, compared to a positive cash flow of ¥818,959,164.52 in Q3 2023, indicating a significant decline[24] - The cash and cash equivalents at the end of Q3 2024 amount to ¥760,317,475.01, down from ¥1,597,855,253.30 at the end of Q3 2023, a decrease of 52.5%[24] Investments and Subsidiaries - The company reported a significant increase in long-term equity investments by 101.24% to CNY 3,653,444.06 due to increased equity method investment income[7] - The company’s long-term equity investments increased from CNY 1,815,466.82 to CNY 3,653,444.06, reflecting a growth of approximately 101.1%[18] - The company’s subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., received approval for a Phase II clinical trial of the innovative drug ZSP1273 for treating influenza in patients aged 2 to 17[14] - The company obtained a drug registration certificate for the innovative drug Lurivite (brand name: Le Ruixing®) in Macau, enabling sales in the region[15] - The company has completed the deregistration of its subsidiary Guangdong Zhonglong Chuangcheng Biotechnology Co., Ltd., aligning with its strategic focus on core business operations[15] - The innovative polypeptide drug RAY1225 injection has received acceptance for a clinical trial application for the treatment of Metabolic Associated Steatotic Liver Disease (MASH)[16] Shareholder Information - The total number of common shareholders at the end of the reporting period was 88,576[10] - Major shareholders Zhang Yuchong and Zhang Yuli each hold 10.88% of shares, totaling 92,640,500 shares[10] - The company transferred 5,551,000 shares to the 2024 employee stock ownership plan, representing 0.65% of the total share capital, at a price of 6.68 per share[13] Expenses - Research and development expenses increased to CNY 86,091,412.48, up 6.06% from CNY 81,119,346.81 year-over-year[21] - The company reported a decrease in sales expenses to CNY 645,880,775.21, down 7.33% from CNY 696,811,016.60[21] - The company reported a 3,220.61% increase in non-operating expenses to 58,696,945.18, primarily due to increased provisions for pending litigation and inventory write-offs[8] - Financial expenses decreased by 64.92% to 6,188,357.25 due to reduced interest expenses from decreased bank loans[8] Other Financial Metrics - The company recorded a credit impairment loss of -6,935,540.55, a 79.20% increase due to increased provisions for bad debts[8] - The company reported a decrease in cash and cash equivalents from CNY 1,252,043,320.29 at the beginning of the period to CNY 766,131,361.53 at the end of the period, representing a decline of approximately 38.7%[17] - The total current assets decreased from CNY 3,960,606,763.22 to CNY 3,260,603,051.47, a reduction of about 17.7%[18] - The company received government subsidies amounting to CNY 1,282,860.20 during the reporting period[4] - The deferred income tax liabilities decreased to CNY 38,173,024.39 from CNY 48,950,943.30, a reduction of 22.01%[19] - The cash inflow from investment activities for Q3 2024 is ¥1,116,898,539.09, compared to ¥412,901,267.65 in Q3 2023, marking an increase of 170.6%[23] - The company received cash from operating activities totaling ¥1,912,197,257.31 in Q3 2024, slightly down from ¥1,943,273,734.78 in Q3 2023, reflecting a decrease of 1.6%[23] - The company reported a decrease in other comprehensive income attributable to the parent company, with a net amount of -¥448,465.64 in Q3 2024 compared to ¥3,741,272.62 in Q3 2023[22]